Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis.

Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Experimental Parasitology (Impact Factor: 2.15). 05/2011; 129(1):55-64. DOI: 10.1016/j.exppara.2011.05.014
Source: PubMed

ABSTRACT The acidic ribosomal proteins of the protozoan parasites have been described as prominent antigens during human disease. We present here data showing the molecular cloning and protective efficacy of P1 gene of Leishmania donovani as DNA vaccine. The PCR amplified complete ORF cloned in either pQE or pVAX vector was used either as peptide or DNA vaccine against experimentally induced visceral leishmaniasis in hamsters. The recombinant protein rLdP1 was given along with Freund's adjuvant and the plasmid DNA vaccine, pVAX-P1 was used alone either as single dose or double dose (prime and boost) in different groups of hamsters which were subsequently challenged with a virulent dose of 1×10(7) L. donovani (MHOM/IN/DD8/1968 strain) promastigotes by intra-cardiac route. While the recombinant protein rLdP1 or DNA vaccine pVAX-P1 in single dose format were not found to be protective, DNA vaccine in a prime-boost mode was able to induce protection with reduced mortality, a significant (75.68%) decrease in splenic parasite burden and increased expression of Th1 type cytokines in immunized hamsters. Histopathology of livers and spleens from these animals showed formation of mature granulomas with compact arrangement of lymphocytes and histiocytes, indicating its protective potential as vaccine candidate.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Disorganized muscle family member (Dim-1) belongs to immunoglobulin superfamily, and is a structural protein localized to the region of the muscle cell membrane around and between the dense bodies. Strong immunogenicity to host's immune system was induced by Dim-1 from Ascaris suum, which indicated that Dim-1 could be a potential candidate for vaccine. The homologues of Dim-1 were also detected in nematodes Brugia malayi and Trichostrongylus colubriformis. However, information on the complete coding sequence and protection potential of this molecule in Haemonchus contortus is lacking. In this study, full length of Dim-1 cDNA was cloned using a rapid amplification of cDNA ends (RACE) strategy and the DNA vaccine encoding Dim-1 open reading frame (ORF) was tested for protection against experimental H. contortus infections in goats. Fifteen goats were allocated into three trial groups. The animals of Dim-1 group were vaccinated with the DNA vaccine encoding Dim-1 on day 0 and 14, and challenged with 5000 infective H. contortus third larval stage (L3) on day 28. An unvaccinated positive control group was challenged with L3 at the same time. An unvaccinated negative control group was not challenged with L3. The results indicated Dim-1 DNA vaccines were transcribed at local injection sites and expressed in vivo post immunizations respectively. Following L3 challenge, the mean eggs per gram feces (EPG) and worm burdens of Dim-1 group were reduced by 45.7% and 51.1%, respectively. Significantly high levels of serum IgG, serum IgA, mucosal IgA, CD4(+) T lymphocytes and B lymphocytes of Dim-1 group were produced. While compared with the negative control group, increased numbers of blood eosinophils and lymphocytes and declined haemoglobin level were observed in the Dim-1 group after L3 challenge. The preliminary study suggest that recombinant H. contortus Dim-1 DNA vaccine induced partial immune response and has protective potential against goat haemonchosis.
    Research in Veterinary Science 03/2013; · 1.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Leishmania (Viannia) shawi parasite was first characterized in 1989. Recently the protective effects of soluble leishmanial antigen (SLA) from L. (V.) shawi promastigotes were demonstrated using BALB/c mice, the susceptibility model for this parasite. In order to identify protective fractions, SLA was fractionated by reverse phase HPLC and five antigenic fractions were obtained. F1 fraction was purified from L. (V.) shawi parasite extract by reverse phase HPLC. BALB/c mice were immunized once a week for two consecutive weeks by subcutaneous routes in the rump, using 25 μg of F1. After 1 and 16 weeks of last immunization, groups were challenged in the footpad with L. (V.) shawi promastigotes. After 2 months, those same mice were sacrificed and parasite burden, cellular and humoral immune responses were evaluated. The F1 fraction induced a high degree of protection associated with an increase in IFN-γ, a decrease in IL-4, increased cell proliferation and activation of CD8+T lymphocytes. Long-term protection was acquired in F1-immunized mice, associated with increased CD4+ central memory T lymphocytes and activation of both CD4+ and CD8+ T cells. In addition, F1-immunized groups showed an increase in IgG2a levels. The inductor capability of antigens to generate memory lymphocytes that can proliferate and secrete beneficial cytokines upon infection could be an important factor in the development of vaccine candidates against American Tegumentary Leishmaniasis.
    Parasites & Vectors 03/2012; 5:64. · 3.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vaccination is the most successful application of immunological principles to human health. Vaccine efficacy needs to be reviewed from time to time and its safety is an overriding consideration. DNA vaccines offer simple yet effective means of inducing broad-based immunity. These vaccines work by allowing the expression of the microbial antigen inside host cells that take up the plasmid. These vaccines function by generating the desired antigen inside the cells, with the advantage that this may facilitate presentation through the major histocompatibility complex. This review article is based on a literature survey and it describes the working and designing strategies of DNA vaccines. Advantages and disadvantages for this type of vaccines have also been explained, together with applications of DNA vaccines. DNA vaccines against cancer, tuberculosis, Edwardsiella tarda, HIV, anthrax, influenza, malaria, dengue, typhoid and other diseases were explored.
    Germs. 03/2013; 3(1):26-35.